Novartis may have another cancer blockbuster on its hands. New Phase III data on Jakavi (ruxolitinib) has Wall Street analysts predicting that it will easily pass the $1 billion mark.
Johnson & Johnson and Pharmacyclics' new drug Imbruvica won the expanded approval it needed to go beyond a rare disease treatment and reach the blockbuster status it was conceived for. The FDA Wednesday gave Imbruvica accelerated approval for treating chronic lymphocytic leukemia in patients who have received at least one previous therapy.
J. Michael Pearson is one ambitious man. The Valeant ($VRX) CEO wants to elbow his way to the top echelons of the drug business. If he has his way, Valeant will be one of the top 5 drugmakers in the world. By 2016.
When Bayer CEO Marijn Dekkers stepped into the job in 2010, he had a trove of cash, and he promised to spend a big chunk on deals. A $23 billion chunk, in fact. Since then, the German conglomerate hasn't exactly been audacious in the M&A arena. Bayer has snapped up a healthcare company or three, but it's quick to back away if a price gets too rich.
Herewith we bring you our Top 15 Drug Launch Superstars. Some of them will be obvious to anyone who follows the pharma business. They certainly were obvious to us. But choosing the rest was a challenge--one we weren't exactly expecting, based on previous experience. Read the full report >>
Lundbeck is fired up and ready for its launch of the potential blockbuster antidepressant Brintellix. Though still awaiting regulatory approval, the Danish drugmaker is recruiting more than 200 sales reps to prepare for take-off, Bloomberg reports.
Bayer said two late-stage tests for Eylea against diabetic macular edema met their primary goals of improving vision compared with laser surgery, meaning that co-developer Regeneron can now submit an application for U.S. marketing approval for that indication later this year--about a year earlier than planned.
A new AARP study worries that Pfizer's aggressive use of price hikes, pay-for-delay deals, and discounts and coupons when Lipitor faced generic competition will become the blueprint for the industry.
Last year, the top 10 cardio drugs racked up sales of $28.644 billion, down 23% from the $37.271 billion they sold in 2011. Still, the group has made a lot of money for its companies for years and, in some cases, completely changed the treatment of heart disease. It is an interesting list. Only Merck has two drugs in the top 10. Read the report >>
Nothing spoke more loudly today of Merck's current worries than its new $15 billion stock-buyback program. But with sales suffering from Singulair generics, an unexpected shortfall in Januvia sales, and a series of recent R&D disappointments to its credit, Merck needs all the investor-relations help it can get.